Mesothelioma

As a cancer survivor, I’ve found three impactful ways to get involved in Mesothelioma Awareness Day to help make a difference.

As a cancer survivor, I’ve found that support from friends and family makes a difference, so here are three ways they can help during survivorship.

After being diagnosed with cancer, I learned that everyone handles grief differently.

Here are four things I found to be helpful as a survivor, including showing up for myself.

As a caregiver, it can be challenging to navigate the holidays.

The Keytruda-Lenvima combination had promising anti-tumor activity for patients with pleural mesothelioma following disease progression after chemotherapy.

Here are ways to become a patient advocate.

I had the wrong interpretation of what a cancer survivor was. That was until I was diagnosed with a rare cancer and shockingly, the term “cancer survivor” became a part of my journey.

After getting over the shock of being diagnosed with a rare cancer, I could only think about returning to my “normal” self, but I later discovered that the normal I was trying to return to would change.

I’ve heard of many stories of friendships dwindling after someone has been diagnosed with cancer. One thing about it is that I can relate.

After being diagnosed with a rare form of cancer — and seeing a clinician who did not know how to treat me — I learned the importance of asking questions to my providers and advocating for myself

Many thoughts went through my mind during cancer, and journaling allowed me to organize them and helped me to feel better.

After being diagnosed with mesothelioma and undergoing a long surgery, I wanted to do it all, but I just couldn’t. Family and friends stepped in to help.

We need to learn more about how to potentially lessen toxins' effects on people's lives.

Imfinzi alone or combined with Imjudo may improve survival and tumor response when administered before surgery, opening the door to neoadjuvant mesothelioma treatments.

Years after I went through mesothelioma, my husband was diagnosed with cancer, causing a reversal in the patient-caregiver roles.

After being diagnosed with mesothelioma, I learned to advocate for myself, and realized that it was an incredibly important life skill to have.

I grew up in a society where mental health was stigmatized, but cancer made me realize that it helps to speak up about these issues.

After being homebound for two years from the COVID-19 pandemic, I was eager to get out, though I did have many cancer/COVID-19 concerns.

Patients with malignant pleural mesothelioma tended to have prolonged benefit when treated with Keytruda plus Lenvima in the PEMMELA clinical trial.

I don’t fit the profile of someone who gets diagnosed with mesothelioma, so my diagnosis came as a shock.

The FDA plans to accelerate its review of IK-930, an investigational drug, for the treatment of patients with unresectable NF2-deficient malignant pleural mesothelioma, a rare cancer.

Part B of the DIONE-01 study will look at whether IOA-244 increases anti-tumor responses in expansion groups of patients.

Imfinzi plus platinum-pemetrexed chemotherapy induced survival improvements in patients with previously untreated, unresectable malignant pleural mesothelioma, compared with chemotherapy alone.

Treatment with the immunotherapy Opdivo for relapsed, malignant mesothelioma may represent a useful choice for patients with minimal therapy options.

The average survival for patients with malignant pleural mesothelioma was less than a month after being diagnosed with COVID-19, according to a small study.

Surgery for malignant pleural mesothelioma after radiotherapy may increase overall survival rates, according to a study. However, study authors note that the procedure should only be adopted in centers with substantial surgical experience.

Mesothelioma has been categorized as an “older persons” disease, writes a 14-year survivor. Which is why, she writes, her and her family were completely caught off-guard when she was diagnosed at 21.

The FDA’s approval or Opdivo (nivolumab) and Yervoy (ipilimumab) for the frontline treatment of patients with unresectable malignant pleural mesothelioma was desperately needed, says a thoracic oncologist at Memorial Sloan Kettering Cancer center. However, some questions remain.

The Food and Drug Administration’s approval of Opdivo in combination with Yervoy for patients with unresectable malignant pleural mesothelioma marks the first new systemic therapy approved in more than 15 years in this setting.